Neurocrine Biosciences
NBIX
#1647
Rank
NZ$22.25 B
Marketcap
NZ$221.78
Share price
1.23%
Change (1 day)
8.59%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Net assets

Net assets on the balance sheet as of December 2025 : NZ$5.45 Billion

According to Neurocrine Biosciences 's latest financial reports the company has NZ$5.45 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Neurocrine Biosciences - Net assets on balance sheet (from 2001 to 2025)

Net assets by year

Year Net assets Change
2025-12-31$NZ$5.61 B22.32%
2024-12-31$NZ$4.59 B30.1%
2023-12-31$NZ$3.52 B31.21%
2022-12-31$NZ$2.68 B33.72%
2021-12-31$NZ$2.01 B28.88%
2020-12-31$NZ$1.56 B65.05%
2019-12-31$NZ$0.94 B31.94%
2018-12-31$NZ$0.71 B36.78%
2017-12-31$NZ$0.52 B15.27%
2016-12-31$NZ$0.45 B-26.7%
2015-12-31$NZ$0.62 B132.83%
2014-12-31$NZ$0.26 B81.78%
2013-12-31$NZ$0.14 B-21.92%
2012-12-31$NZ$0.18 B143.76%
2011-12-31$NZ$76.98 M207.01%
2010-12-31$NZ$25.07 M360.61%
2009-12-31$NZ$5.44 M-91.41%
2008-12-31$NZ$63.36 M-59.11%
2007-12-31$NZ$0.15 B-65.31%
2006-12-31$NZ$0.44 B-21.73%
2005-12-31$NZ$0.57 B3.41%
2004-12-31$NZ$0.55 B-8.27%
2003-12-31$NZ$0.60 B40.42%
2002-12-31$NZ$0.42 B-42.67%
2001-12-31$NZ$0.74 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
Pfizer
PFE
NZ$156.12 B 2,761.76%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
-NZ$4.36 Billion-179.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$44.49 B 715.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$3.49 B-35.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$61.04 Million-101.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$0.84 B-84.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ$0.66 M-99.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$16.29 B 198.64%๐Ÿ‡ฌ๐Ÿ‡ง UK